TABLE OF CONTENTS
Volume 79, Issue 5 (May 2006)
Pharmacogenetic and genomics |
Pharmacokinetics and drug disposition |
Corrections |
Letter to the Editor |
Corrections
Commentaries
Clinical Pharmacology & Therapeutics
C. Michael Stein MD
Clin Pharmacol Ther 79: 401-403; doi:10.1016/j.clpt.2006.03.009
Toward individualized analgesic therapy: Functional cyclooxygenase 1 and 2 haplotypes
Marc K. Halushka MD, PhD and Perry V. Halushka PhD, MD
Clin Pharmacol Ther 79: 404-406; doi:10.1016/j.clpt.2006.02.005
Pharmacogenetic and genomics
Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs
Yun-Sil Lee DDS, MS, Hyungsuk Kim DDS, PhD, Tian-Xia Wu PhD, Xiao-Min Wang MD, PhD and Raymond A. Dionne DDS, PhD
Clin Pharmacol Ther 79: 407-418; doi:10.1016/j.clpt.2006.01.013
Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin
Michael Igel MD, Katja A. Arnold PhD, Mikko Niemi MD, Ute Hofmann PhD, Matthias Schwab MD, Dieter Lütjohann PhD, Klaus von Bergmann MD, Michel Eichelbaum MD and Kari T. Kivistö MD
Clin Pharmacol Ther 79: 419-426; advance online publication, April 11, 2006; doi:10.1016/j.clpt.2006.01.010
Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril
Kazuya Maeda MS, Ichiro Ieiri PhD, Kuninobu Yasuda MD, Akiharu Fujino PhD, Hiroaki Fujiwara PhD, Kenji Otsubo PhD, Masaru Hirano MS, Takao Watanabe MS, Yoshiaki Kitamura MS, Hiroyuki Kusuhara PhD and Yuichi Sugiyama PhD
Clin Pharmacol Ther 79: 427-439; advance online publication, April 11, 2006; doi:10.1016/j.clpt.2006.01.011
Pharmacokinetics and drug disposition
Erythromycin breath test results in elderly, very elderly, and frail elderly persons
Janice B. Schwartz MD
Clin Pharmacol Ther 79: 440-448; advance online publication, April 11, 2006; doi:10.1016/j.clpt.2006.01.006
Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4–dependent pharmacokinetics in humans
Laurent Becquemont MD, PhD, Hartmut Glaeser PhD, Siegfried Drescher MD, Monika Hitzl PhD, Nicolas Simon MD, PhD, Thomas E. Murdter PhD, Georg Heinkele BSc, Ute Hofmann PhD, Christian Schaefer MD, Oliver Burk PhD, Céline Verstuyft PharmD, PhD, Michel Eichelbaum MD and Martin F. Fromm MD
Clin Pharmacol Ther 79: 449-460; advance online publication, April 11, 2006; doi:10.1016/j.clpt.2006.01.005
Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites
Bojan Lalovic PhD, Evan Kharasch MD, PhD, Christine Hoffer BS, Linda Risler BS, Lee-Yuan Liu-Chen PhD and Danny D. Shen PhD
Clin Pharmacol Ther 79: 461-479; doi:10.1016/j.clpt.2006.01.009
Female sex and oral contraceptive use accelerate nicotine metabolism
Neal L. Benowitz MD, Christina N. Lessov-Schlaggar PhD, Gary E. Swan PhD and Peyton Jacob III PhD
Clin Pharmacol Ther 79: 480-488; doi:10.1016/j.clpt.2006.01.008
Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2–mediated theophylline metabolism by fluvoxamine
Rocco Orlando MD, Roberto Padrini MD, Mauro Perazzi PharmD, Sara De Martin PhD, Pierpaolo Piccoli PhD and Pietro Palatini PhD
Clin Pharmacol Ther 79: 489-499; doi:10.1016/j.clpt.2006.01.012
Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects
Karsten Heusser MD, Jens Tank MD, Andre Diedrich MD, Stefan Engeli MD, Susanne Klaua MD, Nadine Krüger, Anke Strauss RN, Gritt Stoffels RN, Friedrich C. Luft MD and Jens Jordan MD
Clin Pharmacol Ther 79: 500-508; doi:10.1016/j.clpt.2006.02.002
Corrections
Corrections FREE
Clin Pharmacol Ther 79: 508; doi:10.1016/j.clpt.2006.03.005
Letter to the Editor
Effect of CYP3A5*3 on carbamazepine pharmacokinetics in Japanese patients with epilepsy
Takayuki Seo MS, Naoyuki Nakada MS, Nao Ueda MS, Takashi Hagiwara MS, Nami Hashimoto MS, Kazuko Nakagawa MD, PhD and Takateru Ishitsu MD
Clin Pharmacol Ther 79: 509-510; doi:10.1016/j.clpt.2006.02.009
